Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce ...

Priority Review granted based on positive results from two Phase 3 trials If approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more ...

Findings from BOREAS and NOTUS showed dupilumab significantly reduced moderate to severe acute COPD exacerbations vs placebo. The Food and Drug Administration (FDA) has accepted for Priority Review ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

Inhalers and nebulizers are necessary when managing chronic obstructive pulmonary disease (COPD). Both are designed to deliver medication directly to the lungs, which helps in reducing symptoms, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 3 BOREAS trial included adults with ...